Literature DB >> 2177207

An evaluation of the distinction of ectopic and pituitary ACTH dependent Cushing's syndrome by clinical features, biochemical tests and radiological findings.

S B Blunt1, L M Sandler, J M Burrin, G F Joplin.   

Abstract

The efficiency of various laboratory and radiological investigations in the differentiation of ectopic from pituitary dependent Cushing's syndrome was studied, based on findings in 23 patients with verified Cushing's disease and seven patients with the ectopic ACTH syndrome. Clinical features strongly favouring the ectopic type were male sex and history for less than 18 months. Basal biochemical features strongly indicating the ectopic syndrome included plasma K+ less than 3.0 mmol/l and HCO3 greater than 30 mmol/l; serum cortisol at 9 a.m. or midnight of greater than 800 nmol/l; urine free cortisol greater than 1300 nmol/24 hours; plasma ACTH greater than 100 ng/l. In the high-dose dexamethasone suppression test, suppression by less than 50 per cent of 9 a.m. serum cortisol, urine free cortisol or 17-oxogenic steroids was usually indicative of an ectopic source of ACTH. A mean suppressed value of greater than 450 nmol/l for the 9 a.m. and midnight cortisol combined occurred in all of those with the ectopic syndrome, but in none of the 23 patients with Cushing's disease. For urine free cortisol, a mean suppressed value of less than 1000 nmol/24 hours was found in all patients with Cushing's disease, but in none of those in the ectopic group. In the metyrapone test, there was an increase of less than or equal to 3-fold in 11-deoxycortisol at 24 hours in patients with ectopic ACTH; the increase was greater than 3-fold in all but one of the patients with Cushing's disease. Failure to respond to either dexamethasone or metyrapone was found in only one of the patients with Cushing's disease (Patient 16); in the ectopic group, all patients except Patient D failed to respond to either test. It is concluded that patients presenting with clinically obvious Cushing's syndrome along with measurable plasma ACTH can be reliably divided by conventional tests into those that are driven from the pituitary and those driven by ectopic ACTH.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2177207     DOI: 10.1093/qjmed/77.2.1113

Source DB:  PubMed          Journal:  Q J Med        ISSN: 0033-5622


  8 in total

1.  Epistaxis and diabetes mellitus in an obese woman.

Authors:  V R Kodali; A Schmitz; N A Harrison
Journal:  Postgrad Med J       Date:  1998-07       Impact factor: 2.401

2.  Ectopic ACTH syndrome: redefinition and case report.

Authors:  O M Jolobe
Journal:  Postgrad Med J       Date:  1996-03       Impact factor: 2.401

3.  An exception to the rule: ectopic ACTH production from functional neuroendocrine tissue in an ovarian dermoid cyst.

Authors:  J Watson; M Taylor; J Pampiglione; S Rasbridge; M Armitage
Journal:  J Endocrinol Invest       Date:  2001-11       Impact factor: 4.256

Review 4.  Adrenocortical hypertension.

Authors:  Angelo Capricchione; Nathaniel Winer; James R Sowers
Journal:  Curr Hypertens Rep       Date:  2004-06       Impact factor: 5.369

Review 5.  Cushing's disease, pseudo-Cushing states and the dexamethasone test: a historical and critical review.

Authors:  J Lindholm
Journal:  Pituitary       Date:  2014-08       Impact factor: 4.107

6.  Development and validation of a novel index for the differential diagnosis of corticotropin-dependent Cushing syndrome.

Authors:  Li Ding; Baoping Wang; Tingting Chen; Ping Li; Weihong Guo; Yuxin Fan; Fang Fang; Jingqiu Cui; Zuoliang Dong; Qing He; Ming Liu
Journal:  Pituitary       Date:  2021-01-27       Impact factor: 4.107

7.  Adrenocortical hypertension.

Authors:  Angelo Capricchione; Nathaniel Winer; James R Sowers
Journal:  Curr Urol Rep       Date:  2006-01       Impact factor: 2.862

8.  Cushing's syndrome complicated by multiple opportunistic infections.

Authors:  R C Bakker; P R Gallas; J A Romijn; W M Wiersinga
Journal:  J Endocrinol Invest       Date:  1998-05       Impact factor: 4.256

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.